Stearns V - Search Results

1

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V. Higgins MJ, et al. Among authors: stearns v. Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Curr Oncol Rep. 2010. PMID: 20425602 Review.

2

Management of hot flashes in breast cancer survivors and men with prostate cancer.

Stearns V. Stearns V. Curr Oncol Rep. 2004 Jul;6(4):285-90. doi: 10.1007/s11912-004-0037-y. Curr Oncol Rep. 2004. PMID: 15161582 Review.

3

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA. Borges S, et al. Among authors: stearns v. Clin Pharmacol Ther. 2006 Jul;80(1):61-74. doi: 10.1016/j.clpt.2006.03.013. Clin Pharmacol Ther. 2006. PMID: 16815318 Free article.

4

Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.

Bao T, Prowell T, Stearns V. Bao T, et al. Among authors: stearns v. Am J Ther. 2006 Jul-Aug;13(4):337-48. doi: 10.1097/00045391-200607000-00011. Am J Ther. 2006. PMID: 16858170 Review.

5

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

Stearns V, Rae JM. Stearns V, et al. Expert Rev Mol Med. 2008 Nov 20;10:e34. doi: 10.1017/S1462399408000896. Expert Rev Mol Med. 2008. PMID: 19019258 Free PMC article. Review.

6

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators. Henry NL, et al. Among authors: stearns v. Breast Cancer Res Treat. 2009 Oct;117(3):571-5. doi: 10.1007/s10549-009-0309-1. Epub 2009 Jan 20. Breast Cancer Res Treat. 2009. PMID: 19153830 Free PMC article. Clinical Trial.

7

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V. Higgins MJ, et al. Among authors: stearns v. J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. doi: 10.6004/jnccn.2009.0014. J Natl Compr Canc Netw. 2009. PMID: 19200418 Review.

8

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

Briest S, Stearns V. Briest S, et al. Among authors: stearns v. Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Clin Adv Hematol Oncol. 2009. PMID: 19398943 Review.

9

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

Higgins MJ, Stearns V. Higgins MJ, et al. Among authors: stearns v. Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18. Clin Chem. 2009. PMID: 19541862 No abstract available.

10

Intraductal therapy for the prevention of breast cancer.

Jacobs L, Sukumar S, Stearns V. Jacobs L, et al. Among authors: stearns v. Curr Opin Investig Drugs. 2010 Jun;11(6):646-52. Curr Opin Investig Drugs. 2010. PMID: 20496259 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page